Unparalleled Precision and Accuracy in the Quantification of pre-Clinical and Clinical Histology

Discover

Unreliable data leads to the failure of drug candidates *

The cost of these failures in terms of finances, lost time and impact on patients is enormous.

The heart of the problem lies in the preclinical models used to evaluate efficacy. These models do not translate well to human disease and are assessed using age-old, qualitative methods that often mask a molecule’s efficacy or lack thereof.

As an example; for NASH the use of pathologist-scored models provides researchers with a qualitative assessment of a molecule’s efficacy. This assessment is subjective, based on a limited area of the sample and is hugely imprecise. The lack of precision and accuracy of this analysis added to the 4-6 weeks that it takes to get this data across a whole study further erode the value of these models.

from pre-clinical stage

90
of drug candidates fail to get approved*.

from clinical stage

54
of these failures are due to lack of efficacy in the clinic*.

*Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results Thomas J. Hwang, AB; Daniel Carpenter, PhD; Julie C. Laffenburger, PhD et al. JAMA Internet. Med. 2016
https://jamanetwork.com/journals/jamainternationmedicine/fullarticle/2565686

Biocellvia’s unique imaging technology banishes variability and brings absolute accuracy to your efficacy data

Our fully automated quantitative assessment plays a critical role by providing researchers with absolute accuracy and precision, delivering results that bring more in-depth insights into their compounds’ efficacy.

Observer-Independent

no bias to the results leading to a better decision making

Scientific support

Project management

Highly accurate, precise and translational

data allowing true comparisons across the development continuum

Image with augmented reality

of each quantified feature for deeper understanding

A turnkey solution!

For each therapeutic area, our specific algorithms were developed by digital imaging specialists and biologists, based on relevant histology. We identify morphometric parameters, quantify them, and interpret them, providing you with a more evident go/no-go decision for your drug candidate. This fully automated, proven and published methodology relies on field-proven-image-processing methods thereby ensuring that researchers obtain the most robust and reproducible data.

Pulmonary Fibrosis

Pulmonary fibrosis is a condition defined by lung scarring, remodelling and decline in function, leading to respiratory failure.
Discover how Biocellvia has driven the shift in the preclinical research to shift from approximative evaluation to extreme accuracy!

Discover

Liver fibrosis /NAFLD-NASH

Nonalcoholic fatty liver disease (NAFLD) has appeared as the next most common chronic liver disease. It progresses to severe hepatic diseases including cirrhosis, liver failure and hepatocellular carcinoma.
Discover how Biocellvia is accelerating science with its dedicated assays supporting preclinical and clinical research!

Discover

Tailor-made Assays

Biocellvia’s R&D team is committed to developing new tools that deliver better preclinical and clinical data to meet your criteria.
Our team, composed of seasoned digital imaging specialists and biologists ensure that clinically and biologically relevant parameters are quantified.

Let's talk about your project

References

logo biocellvia

on Linkedin

We keep you informed about interesting applications,
important dates and innovations through regular updates.

Follow us